Exciting Participation of Keros Therapeutics in Major Conferences
Keros Therapeutics, Inc. is making significant strides in the biopharmaceutical landscape by focusing on innovative therapies targeting disorders associated with the TGF-ß family of proteins. Recently, the company announced that its Chair and Chief Executive Officer, Jasbir S. Seehra, Ph.D., will represent Keros at two major upcoming healthcare conferences.
Details on Conference Participation
At the TD Cowen 45th Annual Healthcare Conference, scheduled for March 3, 2025, at 9:50 a.m. Eastern time, Dr. Seehra will engage in a fireside chat presentation. This event offers an exciting opportunity for Keros to share insights regarding its groundbreaking research and development initiatives.
Conference 1: TD Cowen Annual Healthcare Conference
During the TD Cowen conference, attendees can expect to learn more about Keros Therapeutics' innovative approaches, particularly in developing therapeutics that could significantly improve patient outcomes. The presentation will be accessible for archived replay on the Keros website.
Conference 2: Leerink Partners Global Healthcare Conference
Additionally, Keros will feature at the Leerink Partners Global Healthcare Conference on March 10, 2025, at 1:40 p.m. Eastern time. This conference is another platform where Keros will highlight its pioneering work in the biopharmaceutical field. Both events are anticipated to enhance Keros's visibility among investors and healthcare professionals alike.
About Keros Therapeutics
Keros Therapeutics, Inc. has emerged as a leader in developing novel therapeutics to treat conditions linked to the TGF-ß family of proteins. These proteins are vital for the growth, repair, and maintenance of various tissues, and Keros is at the forefront of discovering treatments that leverage this understanding.
Therapeutic Innovations
The company is advancing several promising product candidates. Cibotercept (KER-012) is in development for treating pulmonary arterial hypertension and cardiovascular disorders. Another key candidate, KER-065, is focused on neuromuscular diseases, showcasing Keros's diverse pipeline aiming to address multifaceted health challenges.
Elritercept (KER-050): A Leading Candidate
Of particular note is elritercept (KER-050), Keros's most advanced candidate, which is being developed to address low blood cell counts, commonly seen in conditions like myelodysplastic syndrome and myelofibrosis. This therapy holds the potential to provide vital support for patients battling these conditions.
Investor Contact Information
For more information, investors can contact Justin Frantz at 617-221-6042 or reach him via email at jfrantz@kerostx.com. Keros Therapeutics is keen to keep potential and current investors informed about its developments and participation in industry events.
Frequently Asked Questions
1. What is Keros Therapeutics focused on?
Keros Therapeutics specializes in developing innovative therapies for disorders linked to the TGF-ß family of proteins, aiming to enhance patient care across various health issues.
2. When will Keros participate in the upcoming healthcare conferences?
Keros will participate in the TD Cowen Annual Healthcare Conference on March 3, 2025, and the Leerink Partners Global Healthcare Conference on March 10, 2025.
3. Who is the CEO of Keros Therapeutics?
The CEO of Keros Therapeutics is Jasbir S. Seehra, Ph.D., who plays a crucial role in leading the company's strategic initiatives.
4. What are the main therapeutic candidates developed by Keros?
Keros is currently developing several candidates, including cibotercept (KER-012) for pulmonary arterial hypertension, KER-065 for neuromuscular diseases, and elritercept (KER-050) for blood cell count disorders.
5. How can investors contact Keros Therapeutics for inquiries?
Investors can reach out to Justin Frantz at 617-221-6042 or via email at jfrantz@kerostx.com for any inquiries regarding the company or its developments.
